High-grade lung adenocarcinoma with fetal lung-like morphology: Clinicopathologic, immunohistochemical, and molecular analyses of 17 cases

American Journal of Surgical Pathology

Volumn 37, Issue 6, 2013, Pages 924-932

  Morita, Shigeki ^a   Yoshida, Akihiko ^a   Goto, Akiteru ^a   Ota, Satoshi ^a   Tsuta, Koji ^a   Yokozawa, Karin ^a   Asamura, Hisao ^b   Nakajima, Jun ^c   Takai, Daiya ^c   Mori, Masaya ^d   Oka, Teruaki ^e   Tamaru, Junichi ^e   Itoyama, Shinji ^e   Furuta, Koh ^a   Fukayama, Masashi ^a   Tsuda, Hitoshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^d MITSUI MEMORIAL HOSPITAL   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma; Fetal; Lung; Neuroendocrine

Indexed keywords

ALPHA FETOPROTEIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROTO ONCOGENE;

ADENOCARCINOMA; ADULT; AGED; ALPHA-FETOPROTEINS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880174819     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31827e1e83     Document Type: Article

References (39)

1. Boyle P, Levin B. World Cancer Report 2008. Lyon: IARC Press, International Agency for Research on Cancer; 2008.
2. Travis WD, et al. World Health Organization, International Agency for Research on Cancer. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon: IARC Press; 2004.
3. Kradin RL, Young RH, Dickersin GR, et al. Pulmonary blastoma with argyrophil cells and lacking sarcomatous features (Pulmonary endodermal tumor resembling fetal lung). Am J Surg Pathol. 1982;6:165-172.
4. Nakatani Y, Dickersin GR, Mark EJ. Pulmonary endodermal tumor resembling fetal lung: a clinicopathologic study of five cases with immunohistochemical and ultrastructural characterization. Hum Pathol. 1990;21:1097-1107.
5. Koss MN, Hochholzer L, O'Leary T. Pulmonary blastomas. Cancer. 1991;67:2368-2381.
6. Mardini G, Pai U, Chavez AM, et al. Endobronchial adenocarci-noma with endometrioid features and prominent neuroendocrine differentiation. A variant of fetal adenocarcinoma. Cancer. 1994;73:1383-1389.
7. Kodama T, Shimosato Y, Watanabe S, et al. Six cases of well-differentiated adenocarcinoma simulating fetal lung tubules in pseudoglandular stage. Comparison with pulmonary blastoma. Am J Surg Pathol. 1984;8:735-744.
8. Nakatani Y, Kitamura H, Inayama Y, et al. Pulmonary adeno-carcinomas of the fetal lung type: a clinicopathologic study indicating differences in histology, epidemiology, and natural history of low-grade and high-grade forms. Am J Surg Pathol. 1998;22:399-411.
9. Nakatani Y, Miyagi Y, Takemura T, et al. Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma-b-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastoma-toid variant of carcinosarcoma. Am J Surg Pathol. 2004;28:921-927.
10. Sekine S, Shibata T, Matsuno Y, et al. b-catenin mutations in pulmonary blastomas: association with morule formation. J Pathol. 2003;200:214-221.
11. Nakatani Y, Masudo K, Miyagi Y, et al. Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules. Mod Pathol. 2002;15:617-624.
12. Sobin LH. Union internationale contre le cancer. TNM Classification of Malignant Tumours. Oxford: Wiley-Blackwell; 2009.
13. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidiscipli-nary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011;8:381-385.
14. Arnould L, Drouot F, Fargeot P, et al. Hepatoid adenocarcinoma of the lung: report of a case of an unusual a-fetoprotein-producing lung tumor. Am J Surg Pathol. 1997;21:1113-1118.
15. Hayashi Y, Takanashi Y, Ohsawa H, et al. Hepatoid adenocarci-noma in the lung. Lung Cancer. 2002;38:211-214.
16. Ishikura H, Kanda M, Ito M, et al. Hepatoid adenocarcinoma: a distinctive histological subtype of alpha-fetoprotein-producing lung carcinoma. Virchows Arch A Pathol Anat Histopathol. 1990;417:73-80.
17. Kishimoto T, Yano T, Hiroshima K, et al. A case of a-fetoprotein- producing pulmonary carcinoma with restricted expression of hepatocyte nuclear factor-4a in hepatoid foci: a case report with studies of previous cases. Hum Pathol. 2008;39:1115-1120.
18. Katzenstein ALA, Prioleau PG, Askin FB. The histologic spectrum and significance of clear-cell change in lung carcinoma. Cancer. 1980;45:943-947.
19. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcino-ma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26:5589-5595.
20. Krypuy M, Newnham GM, Thomas DM, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 2006;6:295.
21. Sato S, Koike T, Yamato Y, et al. Resected well-differentiated fetal pulmonary adenocarcinoma and summary of 25 cases reported in Japan. Jpn J Thorac Cardiovasc Surg. 2006;54:539-542.
22. Howe M, Chapman A, Kerr K, et al. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology. 2005;46:195-201.
23. Ionescu DN, Treaba D, Gilks CB, et al. Nonsmall cell lung carcinoma with neuroendocrine differentiation-An entity of no clinical or prognostic significance. Am J Surg Pathol. 2007;31:26-32.
24. Segawa Y, Takata S, Fujii M, et al. Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. J Cancer Res Clin Oncol. 2009;135:1055-1059.
25. Chang YC, Nagasue N, Abe S, et al. Comparison between the clinicopathologic features of AFP-positive and AFP-negative gastric cancers. Am J Gastroenterol. 1992;87:321-325.
26. Maitra A, Murakata LA, Albores-Saavedra J. Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract. Am J Clin Pathol. 2001;115:689-694.
27. Kodama T, Kameya T, Hirota T, et al. Production of alpha-fetoprotein, normal serum proteins, and human chorionic gonado-tropin in stomach cancer: Histologic and immunohistochemical analyses of 35 cases. Cancer. 1981;48:1647-1655.
28. Motoyama T, Aizawa K, Watanabe H, et al. alpha-Fetoprotein producing gastric carcinomas: a comparative study of three different subtypes. Acta Pathol Jpn. 1993;43:654-661.
29. Ushiku T, Uozaki H, Shinozaki A, et al. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and a-fetoprotein-producing gastric carcinomas. Cancer Sci. 2009;100:626-632.
30. Matsunou H, Konishi F, Jalal RE, et al. Alpha-fetoprotein-producing gastric carcinoma with enteroblastic differentiation. Cancer. 1994;73:534-540.
31. Ushiku T, Shinozaki A, Shibahara J, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol. 2010;34:533-540.
32. Hishinuma M, Ohashi K, Yamauchi N, et al. Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for a-fetoprotein-producing gastric carcinoma. Histopathology. 2006;49:479-486.
33. Kumashiro Y, Yao T, Aishima S, et al. Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype. Hum Pathol. 2007;38:857-863.
34. Mizoshita T, Tsukamoto T, Nakanishi H, et al. Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis. J Cancer Res Clin Oncol. 2003;129:727-734.
35. Kosaka T, Yatabe Y, Onozato R, et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2009;4:22-29.
36. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513-2520.
37. Haneda H, Sasaki H, Lindeman N, et al. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn J Clin Oncol. 2006;36:69-75.
38. Brambilla E, Gazzeri S, Moro D, et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol. 1993;143: 199-210.
39. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer. J Clin Oncol. 2007;25:5240-5247.